Suchergebnisse - "Stagno, Fabio"

PubPharm (18)

1

Dasatinib first-line : Multicentric Italian experience outside clinical trials

enthalten in: Leukemia research | 2016

von Breccia, M. | Stagno, F. | Luciano, L. | +27

2

Dasatinib first-line: Multicentric Italian experience outside clinical trials

enthalten in: Leukemia research | 2016

von Breccia, M. | Stagno, F. | Luciano, L. | +27

3

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

enthalten in: Leukemia research | 2015

von Breccia, M. | Efficace, F. | Sica, S. | +31

4

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

enthalten in: Leukemia research | 2015

von Breccia, M. | Efficace, F. | Sica, S. | +31

5

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

enthalten in: Leukemia research | 2014

von Breccia, M. | Luciano, L. | Latagliata, R. | +33

CommentIn: Leuk Res. 2014 Oct;38(10):1156-7. - PMID 25113280

6

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

enthalten in: Leukemia research | 2014

von Breccia, M. | Luciano, L. | Latagliata, R. | +33

7

Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment

enthalten in: Leukemia research | 2012

von Stagno, F. | Vigneri, P. | Cupri, A. | +2

CommentOn: Leuk Res. 2012 Jun;36(6):689-93. - PMID 22398220

8

Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment

enthalten in: Leukemia research | 2012

von Stagno, F. | Vigneri, P. | Cupri, A. | +2

9

Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia

enthalten in: Leukemia research | 2012

von Stagno, F. | Vigneri, P. | Di Raimondo, F.

10

Towards a need to a “biological Sokal risk” in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia

enthalten in: Leukemia research | 2012

von Stagno, F. | Vigneri, P. | Di Raimondo, F.